Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancerYoshikazu Johmura, Makoto Nakanishi, Wenwen Wu et al.|Journal of Clinical Investigation|2018Cited by 78
Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinomaSaki Nakagawa, Takanori Ishida, Minoru Miyashita et al.|Breast Cancer Research and Treatment|2024Cited by 2